|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,624.25 DKK | +0.48% |
|
+0.74% | -19.93% |
| 06-11 | Genmab Says Subgroup Data for Follicular Lymphoma Treatment Shows 'Sustained' Efficacy Benefits | MT |
| 06-10 | Nordic stocks in North America - Autoliv rose 1.6 percent | FW |
Main competitors
| Consensus | Analysts' target price evolution (4 months) | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Average Target P. | Objective/dr gap | Nbr of analysts | ||
|---|---|---|---|---|---|---|---|---|---|
 | 2,313.13 | +43.09% | 15 | ||||||
| 846.68 | +9.16% | 15 | ||||||
| 145.96 | +50.37% | 16 | ||||||
| 106.48 | +38.24% | 19 | ||||||
| 198.1 | +104.81% | 21 | ||||||
| 40.49 | +56.7% | 22 | ||||||
| 49 | -8.41% | 16 | ||||||
| 547.64 | +38.85% | 17 | ||||||
| 810.5 | -13.22% | 6 | ||||||
| 678.71 | +43.1% | 14 | ||||||
| 148.85 | +96.09% | 20 | ||||||
| 21.28 | +117.9% | 13 | ||||||
| 88.17 | +18.49% | 12 | ||||||
| 128.12 | +3.79% | 16 | ||||||
| 104.7 | +51.15% | 20 | ||||||
| 13 | +80.56% | 3 | ||||||
| 99.79 | +65.73% | 15 | ||||||
| 414.05 | -0.46% | 20 | ||||||
| - | - | 770,000 | +77.42% | 1 | ||||
| 109 | +130.49% | 9 | ||||||
| Average | 38,843.18 | +50.19% | 14 | ||||||
| Weighted average by Cap. | 18,135.62 | +43.72% | 16 |
- Stock Market
- Stocks
- GMAB Stock
- Sector Genmab A/S
- Sector consensus
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition